<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652610</url>
  </required_header>
  <id_info>
    <org_study_id>205343</org_study_id>
    <secondary_id>V59_71</secondary_id>
    <secondary_id>2017-003692-61</secondary_id>
    <nct_id>NCT03652610</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age</brief_title>
  <official_title>Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by&#xD;
      meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more&#xD;
      than 60 countries.&#xD;
&#xD;
      The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY&#xD;
      vaccine with the investigational MenACWY liquid vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Actual">June 11, 2019</completion_date>
  <primary_completion_date type="Actual">January 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Data will be collected in an observer-blind manner. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity and immunogenicity) will all be unaware of which vaccine was administered. To do so, vaccine preparation and administration will be done by authorized medical personnel who will not participate in any of the study clinical evaluations.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group, and Between-group Ratios</measure>
    <time_frame>At Day 29</time_frame>
    <description>hSBA titers against N.meningitidis serogroup A were calculated in terms of GMTs adjusted for pre-vaccination titer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs Against Each of the N.Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Ratios</measure>
    <time_frame>At Day 1 and Day 29</time_frame>
    <description>hSBA titers were calculated in terms of GMTs, at Day 1 and Day 29, against each of the N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within-group Geometric Mean Ratios (GMRs) Against Each of the N.Meningitidis Serogroups A, C, W and Y</measure>
    <time_frame>At Day 29</time_frame>
    <description>Within-group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With a ≥4 Fold Rise in hSBA Antibody Titers for Each of the N.Meningitidis Serogroups A, C,W and Y for Each Vaccine Group, and Between-group Differences</measure>
    <time_frame>At Day 29</time_frame>
    <description>The percentages of subjects with a ≥ 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs were computed by group and for each N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as: for individuals, whose pre-vaccination titers are &lt; the LOD (limit of detection), the post-vaccination titers must be ≥ 4-fold the LOD or ≥ the LLOQ (lower of limit of quantitation) whichever is greater; for individuals, whose pre-vaccination titers are ≥ the LOD and ≤ the LLOQ, the post-vaccination titers must be at least four times the LLOQ; for individuals whose pre-vaccination titers are &gt; the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥8 Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</measure>
    <time_frame>At Day 1 and Day 29</time_frame>
    <description>For each vaccine group the percentage of subjects with hSBA titer ≥8, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</measure>
    <time_frame>At Day 1 and Day 29</time_frame>
    <description>For each vaccine group the percentage of subjects with hSBA titer ≥LLOQ, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Solicited Local and Systemic AEs</measure>
    <time_frame>From Day 1 (6 hours) to Day 7 after vaccination</time_frame>
    <description>Number of subjects with solicited local and systemic AEs during the 7-days period (including the day of vaccination) after the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Other Indicators of Reactogenicity</measure>
    <time_frame>From Day 1 to Day 7 after vaccination</time_frame>
    <description>Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Any Unsolicited AEs Within 29 Days After Vaccination</measure>
    <time_frame>From Day 1 to Day 29 after vaccination</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With AEs Leading to Withdrawal, Medically Attended AEs and Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 1 to Day 181 (during the entire study period)</time_frame>
    <description>Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported With Any Unsolicited Adverse Events (AEs) Within 30 Minutes After Vaccination</measure>
    <time_frame>Within 30 minutes after vaccination at Day 1</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">996</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>GSK3536820A ACWY_Liq Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACWY Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)</intervention_name>
    <description>Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm</description>
    <arm_group_label>GSK3536820A ACWY_Liq Group</arm_group_label>
    <other_name>GSK3536820A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed GSK MenACWY vaccine (Menveo)</intervention_name>
    <description>Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm</description>
    <arm_group_label>ACWY Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who, in the opinion of the investigator, can and will comply with the&#xD;
             requirements of the protocol or subjects' parent(s)/Legally Acceptable&#xD;
             Respresentative(s) [LAR(s)] who, in the opinion of the investigator, can and will&#xD;
             comply, with the requirements of the protocol.&#xD;
&#xD;
          2. Written informed consent obtained from the subject/from the parents(s)/LAR(s) of the&#xD;
             subject prior to performance of any study specific procedure.&#xD;
&#xD;
          3. Written informed assent obtained for subjects below legal age of consent, if required&#xD;
             by local regulations, at the time of enrolment.&#xD;
&#xD;
          4. A male or female between, and including, ≥18 to ≤40 YoA at the time of the first&#xD;
             vaccination.&#xD;
&#xD;
          5. Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          6. Female subjects of non-childbearing potential may be enrolled in the study.&#xD;
&#xD;
               -  Non-childbearing potential is defined as pre-menarche, current bilateral tubal&#xD;
                  ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.&#xD;
&#xD;
          7. Female subjects of childbearing potential may be enrolled in the study, if the&#xD;
             subject:&#xD;
&#xD;
               -  has practiced adequate contraception for 30 days prior to vaccination, and&#xD;
&#xD;
               -  has a negative pregnancy test on the day of vaccination, and&#xD;
&#xD;
               -  has agreed to continue adequate contraception during the entire treatment period.&#xD;
                  (approximately 1 month after vaccination).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anaphylaxis following the administration of vaccine&#xD;
&#xD;
          2. Any (clinical) condition that in the judgment of the investigator would make&#xD;
             intramuscular injection unsafe and/or represents a contraindication to intramuscular&#xD;
             vaccination and blood draws.&#xD;
&#xD;
          3. Any confirmed or suspected immunosuppressive or immunodeficient condition, including&#xD;
             HIV infection.&#xD;
&#xD;
          4. Progressive, unstable or uncontrolled clinical conditions.&#xD;
&#xD;
          5. Hypersensitivity, including allergy, to any component of vaccines, medicinal products&#xD;
             or medical equipment whose use is foreseen in this study.&#xD;
&#xD;
          6. Hypersensitivity to the active substances or to any of the excipients of the vaccine,&#xD;
             including diphtheria toxoid (CRM197), or a life-threatening reaction after previous&#xD;
             administration of a vaccine containing similar components.&#xD;
&#xD;
          7. Abnormal function of the immune system resulting from:&#xD;
&#xD;
               -  Clinical conditions.&#xD;
&#xD;
               -  Systemic administration of corticosteroids (Per os [PO]/ Intravenous [IV]/&#xD;
                  Intramuscular [IM]) for more than 14 consecutive days within 90 days prior to&#xD;
                  informed consent, and until the Day 29 blood draw.&#xD;
&#xD;
               -  Administration of antineoplastic and immuno-modulating agents or radiotherapy&#xD;
                  within 90 days prior to informed consent, and until the Day 29 blood draw.&#xD;
&#xD;
          8. Received immunoglobulins or any blood products within 180 days prior to informed&#xD;
             consent.&#xD;
&#xD;
          9. Received an investigational or non-registered medicinal product within 30 days prior&#xD;
             to informed consent.&#xD;
&#xD;
         10. Any other clinical condition that, in the opinion of the investigator, might interfere&#xD;
             with the results of the study or pose additional risk to the subject due to&#xD;
             participation in the study.&#xD;
&#xD;
         11. History of any meningococcal vaccination.&#xD;
&#xD;
         12. Individuals who received any other vaccines within 7 days (for inactivated vaccines)&#xD;
             or 14 days (for live vaccines) prior to enrolment in this study or who are planning to&#xD;
             receive any vaccine within 28 days from the study vaccines*.&#xD;
&#xD;
             * In case an emergency mass vaccination for an unforeseen public health threat (e.g.:&#xD;
             a pandemic) is organised by the public health authorities, outside the routine&#xD;
             immunization program, the time period described above can be reduced if necessary for&#xD;
             that vaccine provided it is licensed and used according to its Summary of Product&#xD;
             Characteristics (SmPC) or Prescribing Information and according to the local&#xD;
             governmental recommendations and provided a written approval of the Sponsor is&#xD;
             obtained.&#xD;
&#xD;
         13. Administration of long-acting immune-modifying drugs at any time during the study&#xD;
             period (e.g. infliximab).&#xD;
&#xD;
         14. Concurrently participating in another clinical study, at any time during the study&#xD;
             period, in which the subject has been or will be exposed to an investigational or a&#xD;
             non-investigational vaccine/product. (pharmaceutical product or device).&#xD;
&#xD;
         15. Current or previous, confirmed or suspected disease caused by N. meningitidis.&#xD;
&#xD;
         16. Household contact with and/or intimate exposure to an individual with any laboratory&#xD;
             confirmed N. meningitidis infection within 60 days prior to study vaccination.&#xD;
&#xD;
         17. Acute disease and/or fever within 3 days prior to study vaccination. Note: enrolment&#xD;
             may be postponed/delayed until such transient circumstances have ended.&#xD;
&#xD;
               -  Fever is defined as body temperature ≥ 38.0°C / 100.4°F. The preferred location&#xD;
                  for measuring temperature in this study will be the oral cavity.&#xD;
&#xD;
               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory&#xD;
                  infection) without fever may be enrolled at the discretion of the investigator.&#xD;
&#xD;
         18. Received systemic antibiotic treatment within 3 days prior to study vaccination or&#xD;
             blood draw.&#xD;
&#xD;
         19. Study personnel as an immediate family or household member.&#xD;
&#xD;
         20. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4222</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1L 0H8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goch</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chieti</city>
        <state>Abruzzo</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Conegliano - Treviso</city>
        <zip>31015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Massafra (TA)</city>
        <zip>74016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Estonia</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <results_first_submitted>January 20, 2021</results_first_submitted>
  <results_first_submitted_qc>January 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 9, 2021</results_first_posted>
  <disposition_first_submitted>January 17, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 25, 2020</disposition_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Liquid formulation</keyword>
  <keyword>Meningococcal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03652610/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03652610/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 8 centers in Australia, 2 in Belgium, 10 in Canada, 6 in Germany and 4 in Italy.Planned age range in this study was 18-40 years.But 1 subject aged 44 years not meeting inclusion criteria was enrolled &amp; vaccinated in GSK3536820A ACWY_Liq Group &amp; therefore was considered for all analyses except per protocol set for immunogenicity analyses</recruitment_details>
      <pre_assignment_details>Among 996 enrolled subjects, 16 subjects didn't receive any treatment and ICF documentation was not retrievable for 1 subject.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK3536820A ACWY_Liq Group</title>
          <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
        </group>
        <group group_id="P2">
          <title>ACWY Group</title>
          <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="490"/>
                <participants group_id="P2" count="489"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="486"/>
                <participants group_id="P2" count="484"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK3536820A ACWY_Liq Group</title>
          <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
        </group>
        <group group_id="B2">
          <title>ACWY Group</title>
          <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="490"/>
            <count group_id="B2" value="489"/>
            <count group_id="B3" value="979"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="5.8"/>
                    <measurement group_id="B2" value="31.9" spread="5.8"/>
                    <measurement group_id="B3" value="31.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="614"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian Or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian Or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="427"/>
                    <measurement group_id="B2" value="439"/>
                    <measurement group_id="B3" value="866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group, and Between-group Ratios</title>
        <description>hSBA titers against N.meningitidis serogroup A were calculated in terms of GMTs adjusted for pre-vaccination titer.</description>
        <time_frame>At Day 29</time_frame>
        <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group, and Between-group Ratios</title>
          <description>hSBA titers against N.meningitidis serogroup A were calculated in terms of GMTs adjusted for pre-vaccination titer.</description>
          <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="404"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.16" lower_limit="147.90" upper_limit="231.81"/>
                    <measurement group_id="O2" value="211.33" lower_limit="169.61" upper_limit="263.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of the investigational MenACWY liquid vaccine with approximately 30% Men A FS (GSK3536820A ACWY_Liq Group) to that of currently licensed MenACWY vaccine (ACWY Group), as measured by the adjusted human serum bactericidal assay (hSBA) Geometric Mean Titers (GMTs) directed against N. meningitidis serogroup A at Day 29 after a single dose vaccination</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the lower limit of the two sided 95% CI for the hSBA GMT ratio for serogroup A is &gt; 0.5</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMTs Against Each of the N.Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Ratios</title>
        <description>hSBA titers were calculated in terms of GMTs, at Day 1 and Day 29, against each of the N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>At Day 1 and Day 29</time_frame>
        <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMTs Against Each of the N.Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Ratios</title>
          <description>hSBA titers were calculated in terms of GMTs, at Day 1 and Day 29, against each of the N. meningitidis serogroups A, C, W and Y.</description>
          <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="2.52" upper_limit="3.10"/>
                    <measurement group_id="O2" value="2.97" lower_limit="2.68" upper_limit="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.96" lower_limit="145.11" upper_limit="230.68"/>
                    <measurement group_id="O2" value="213.42" lower_limit="170.11" upper_limit="267.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="459"/>
                    <count group_id="O2" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.41" lower_limit="9.81" upper_limit="13.27"/>
                    <measurement group_id="O2" value="12.05" lower_limit="10.38" upper_limit="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.95" lower_limit="115.03" upper_limit="206.04"/>
                    <measurement group_id="O2" value="139.63" lower_limit="104.56" upper_limit="186.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="455"/>
                    <count group_id="O2" value="457"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="8.05" upper_limit="11.45"/>
                    <measurement group_id="O2" value="10.92" lower_limit="9.16" upper_limit="13.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.74" lower_limit="47.67" upper_limit="74.86"/>
                    <measurement group_id="O2" value="54.12" lower_limit="43.17" upper_limit="67.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="458"/>
                    <count group_id="O2" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="3.63" upper_limit="4.71"/>
                    <measurement group_id="O2" value="4.75" lower_limit="4.17" upper_limit="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                    <count group_id="O2" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.29" lower_limit="48.67" upper_limit="74.68"/>
                    <measurement group_id="O2" value="54.99" lower_limit="44.44" upper_limit="68.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To compare the immunogenicity of the investigational MenACWY liquid vaccine with approximately 30% Men A FS (GSK3536820A ACWY_Liq Group) and the currently licensed MenACWY vaccine (ACWY Group), as measured by the adjusted hSBA GMTs directed against N. meningitidis serogroup C at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To compare the immunogenicity of the investigational MenACWY liquid vaccine with approximately 30% Men A FS (GSK3536820A ACWY_Liq Group) and the currently licensed MenACWY vaccine (ACWY Group), as measured by the adjusted hSBA GMTs directed against N. meningitidis serogroup W at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To compare the immunogenicity of the investigational MenACWY liquid vaccine with approximately 30% Men A FS (GSK3536820A ACWY_Liq Group) and the currently licensed MenACWY vaccine (ACWY Group), as measured by the adjusted hSBA GMTs directed against N. meningitidis serogroup Y at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-group Geometric Mean Ratios (GMRs) Against Each of the N.Meningitidis Serogroups A, C, W and Y</title>
        <description>Within-group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.</description>
        <time_frame>At Day 29</time_frame>
        <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Within-group Geometric Mean Ratios (GMRs) Against Each of the N.Meningitidis Serogroups A, C, W and Y</title>
          <description>Within-group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.</description>
          <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="455"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.24" lower_limit="51.81" upper_limit="82.16"/>
                    <measurement group_id="O2" value="73.01" lower_limit="58.26" upper_limit="91.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.17" lower_limit="10.30" upper_limit="16.84"/>
                    <measurement group_id="O2" value="11.07" lower_limit="8.68" upper_limit="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.07" upper_limit="7.33"/>
                    <measurement group_id="O2" value="4.8" lower_limit="3.99" upper_limit="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                    <count group_id="O2" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.64" lower_limit="11.88" upper_limit="18.04"/>
                    <measurement group_id="O2" value="11.48" lower_limit="9.33" upper_limit="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With a ≥4 Fold Rise in hSBA Antibody Titers for Each of the N.Meningitidis Serogroups A, C,W and Y for Each Vaccine Group, and Between-group Differences</title>
        <description>The percentages of subjects with a ≥ 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs were computed by group and for each N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as: for individuals, whose pre-vaccination titers are &lt; the LOD (limit of detection), the post-vaccination titers must be ≥ 4-fold the LOD or ≥ the LLOQ (lower of limit of quantitation) whichever is greater; for individuals, whose pre-vaccination titers are ≥ the LOD and ≤ the LLOQ, the post-vaccination titers must be at least four times the LLOQ; for individuals whose pre-vaccination titers are &gt; the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination</description>
        <time_frame>At Day 29</time_frame>
        <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With a ≥4 Fold Rise in hSBA Antibody Titers for Each of the N.Meningitidis Serogroups A, C,W and Y for Each Vaccine Group, and Between-group Differences</title>
          <description>The percentages of subjects with a ≥ 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs were computed by group and for each N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as: for individuals, whose pre-vaccination titers are &lt; the LOD (limit of detection), the post-vaccination titers must be ≥ 4-fold the LOD or ≥ the LLOQ (lower of limit of quantitation) whichever is greater; for individuals, whose pre-vaccination titers are ≥ the LOD and ≤ the LLOQ, the post-vaccination titers must be at least four times the LLOQ; for individuals whose pre-vaccination titers are &gt; the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination</description>
          <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="455"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" lower_limit="75.4" upper_limit="83.7"/>
                    <measurement group_id="O2" value="83.7" lower_limit="79.7" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="51.5" upper_limit="61.0"/>
                    <measurement group_id="O2" value="54.4" lower_limit="49.6" upper_limit="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="40.0" upper_limit="49.5"/>
                    <measurement group_id="O2" value="40.2" lower_limit="35.6" upper_limit="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                    <count group_id="O2" value="455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" lower_limit="58.6" upper_limit="67.7"/>
                    <measurement group_id="O2" value="58" lower_limit="53.3" upper_limit="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup A at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-3.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.30</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup C at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.70</ci_lower_limit>
            <ci_upper_limit>8.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup W at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>4.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>11.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentage of subjects with a ≥ 4-fold rise in post-vaccination hSBA for N. meningitidis serogroup Y at Day 29.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>5.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>11.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥8 Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</title>
        <description>For each vaccine group the percentage of subjects with hSBA titer ≥8, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>At Day 1 and Day 29</time_frame>
        <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥8 Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</title>
          <description>For each vaccine group the percentage of subjects with hSBA titer ≥8, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
          <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="460"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.3" upper_limit="11.8"/>
                    <measurement group_id="O2" value="11.2" lower_limit="8.4" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="78.7" upper_limit="86.3"/>
                    <measurement group_id="O2" value="86.4" lower_limit="82.8" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="459"/>
                    <count group_id="O2" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="49.1" upper_limit="58.4"/>
                    <measurement group_id="O2" value="54.4" lower_limit="49.7" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" lower_limit="70.2" upper_limit="78.5"/>
                    <measurement group_id="O2" value="74.9" lower_limit="70.6" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="455"/>
                    <count group_id="O2" value="457"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="35.3" upper_limit="44.4"/>
                    <measurement group_id="O2" value="45.7" lower_limit="41.1" upper_limit="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="454"/>
                    <count group_id="O2" value="457"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" lower_limit="69.0" upper_limit="77.4"/>
                    <measurement group_id="O2" value="73.1" lower_limit="68.8" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="458"/>
                    <count group_id="O2" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="18.9" upper_limit="26.8"/>
                    <measurement group_id="O2" value="25.5" lower_limit="21.6" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="460"/>
                    <count group_id="O2" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="73.1" upper_limit="80.9"/>
                    <measurement group_id="O2" value="76" lower_limit="71.9" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup A at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-2.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.47</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup C at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.99</ci_lower_limit>
            <ci_upper_limit>5.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup W at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-5.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.33</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup Y at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.30</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup A at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.65</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup C at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.12</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup W at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.49</ci_lower_limit>
            <ci_upper_limit>6.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥8 for the N. meningitidis serogroup Y at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.33</ci_lower_limit>
            <ci_upper_limit>6.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</title>
        <description>For each vaccine group the percentage of subjects with hSBA titer ≥LLOQ, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
        <time_frame>At Day 1 and Day 29</time_frame>
        <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against Each of the N. Meningitidis Serogroups A, C, W and Y for Each Vaccine Group, and Between-group Differences</title>
          <description>For each vaccine group the percentage of subjects with hSBA titer ≥LLOQ, and its associated two-sided 95% Clopper-Pearson CIs were computed for each of the N. meningitidis serogroups A, C, W and Y.</description>
          <population>Analysis was performed on the per protocol set for immunogenicity that includes subjects who received the vaccine, did not have any protocol deviation leading to exclusion, who were not excluded due to other reasons defined prior to unblinding or analysis and had available immuno data for any serogroup and time point considered.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="460"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis A, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="7.8" upper_limit="13.8"/>
                    <measurement group_id="O2" value="13.5" lower_limit="10.4" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="78.7" upper_limit="86.3"/>
                    <measurement group_id="O2" value="86.7" lower_limit="83.1" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="459"/>
                    <count group_id="O2" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" lower_limit="56.6" upper_limit="65.7"/>
                    <measurement group_id="O2" value="62.3" lower_limit="57.7" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="72.3" upper_limit="80.4"/>
                    <measurement group_id="O2" value="76.5" lower_limit="72.2" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="455"/>
                    <count group_id="O2" value="457"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="36.8" upper_limit="46.0"/>
                    <measurement group_id="O2" value="47.3" lower_limit="42.6" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="454"/>
                    <count group_id="O2" value="457"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" lower_limit="69.0" upper_limit="77.4"/>
                    <measurement group_id="O2" value="73.5" lower_limit="69.2" upper_limit="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="458"/>
                    <count group_id="O2" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="20.0" upper_limit="28.0"/>
                    <measurement group_id="O2" value="26.3" lower_limit="22.4" upper_limit="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="460"/>
                    <count group_id="O2" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="73.7" upper_limit="81.5"/>
                    <measurement group_id="O2" value="77.3" lower_limit="73.2" upper_limit="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup A at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-2.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.24</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup C at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.34</ci_lower_limit>
            <ci_upper_limit>5.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup W at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-5.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.35</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup Y at Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.15</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup A at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-3.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.87</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup C at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.52</ci_lower_limit>
            <ci_upper_limit>5.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup W at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.92</ci_lower_limit>
            <ci_upper_limit>5.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-group difference in percentages of subjects with hSBA titer ≥LLOQ for the N. meningitidis serogroup Y at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in percentage of subjects</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.89</ci_lower_limit>
            <ci_upper_limit>5.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Solicited Local and Systemic AEs</title>
        <description>Number of subjects with solicited local and systemic AEs during the 7-days period (including the day of vaccination) after the vaccination.</description>
        <time_frame>From Day 1 (6 hours) to Day 7 after vaccination</time_frame>
        <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported any solicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Solicited Local and Systemic AEs</title>
          <description>Number of subjects with solicited local and systemic AEs during the 7-days period (including the day of vaccination) after the vaccination.</description>
          <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported any solicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Temperature &gt;= 38 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Other Indicators of Reactogenicity</title>
        <description>Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after vaccination</description>
        <time_frame>From Day 1 to Day 7 after vaccination</time_frame>
        <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported any indicators of reactogenicity data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Other Indicators of Reactogenicity</title>
          <description>Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after vaccination</description>
          <population>Analysis was performed on the solicited safety set that includes all enrolled subjects who received a study vaccination and reported any indicators of reactogenicity data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analgesic/Antipyretic Prevention, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Prevention, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453"/>
                    <measurement group_id="O2" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Treatment, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Treatment, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409"/>
                    <measurement group_id="O2" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Any Unsolicited AEs Within 29 Days After Vaccination</title>
        <description>An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>From Day 1 to Day 29 after vaccination</time_frame>
        <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Any Unsolicited AEs Within 29 Days After Vaccination</title>
          <description>An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
          <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With AEs Leading to Withdrawal, Medically Attended AEs and Serious Adverse Events (SAEs)</title>
        <description>Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity</description>
        <time_frame>From Day 1 to Day 181 (during the entire study period)</time_frame>
        <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported any adverse events data in the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With AEs Leading to Withdrawal, Medically Attended AEs and Serious Adverse Events (SAEs)</title>
          <description>Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity</description>
          <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported any adverse events data in the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aes leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported With Any Unsolicited Adverse Events (AEs) Within 30 Minutes After Vaccination</title>
        <description>An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Within 30 minutes after vaccination at Day 1</time_frame>
        <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3536820A ACWY_Liq Group</title>
            <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
          </group>
          <group group_id="O2">
            <title>ACWY Group</title>
            <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported With Any Unsolicited Adverse Events (AEs) Within 30 Minutes After Vaccination</title>
          <description>An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.</description>
          <population>Analysis was performed on the unsolicited safety set that includes all enrolled subjects who received a study vaccination and reported unsolicited adverse events data for the defined period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected from Day 1 to Day 7 after vaccination and Unsolicited AEs from Day 1 to Day 29 after vaccination. SAEs were collected from Day 1 to Day 181 (during the entire study period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK3536820A ACWY_Liq Group</title>
          <description>Healthy adults, 18 to 44 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.</description>
        </group>
        <group group_id="E2">
          <title>ACWY Group</title>
          <description>Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="490"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiplegic migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="336" subjects_at_risk="490"/>
                <counts group_id="E2" subjects_affected="335" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="52" subjects_affected="51" subjects_at_risk="490"/>
                <counts group_id="E2" events="52" subjects_affected="51" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site joint pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="44" subjects_affected="43" subjects_at_risk="490"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="163" subjects_affected="160" subjects_at_risk="490"/>
                <counts group_id="E2" events="163" subjects_affected="162" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="490"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="490"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="204" subjects_affected="200" subjects_at_risk="490"/>
                <counts group_id="E2" events="184" subjects_affected="184" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="490"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Vaccination site paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="490"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="490"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="490"/>
                <counts group_id="E2" events="42" subjects_affected="41" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="43" subjects_at_risk="490"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="490"/>
                <counts group_id="E2" events="58" subjects_affected="58" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Myosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="167" subjects_affected="162" subjects_at_risk="490"/>
                <counts group_id="E2" events="183" subjects_affected="171" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="490"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Sensitive skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="490"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="490"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="489"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

